FMNL1 and lymphoma: The overexpression of FMNL1 in blood-derived tumor cells has led to the development of novel approaches to cancer treatment, such as the use of cytotoxic T cell clones with T cell receptors specific to an FMNL1 peptide to treat lymphomas and other malignancies of cells of the immune system [347].